Stephens Investment Management Group LLC lifted its position in ResMed Inc. (NYSE:RMD) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 357,493 shares of the medical equipment provider’s stock after buying an additional 1,638 shares during the quarter. Stephens Investment Management Group LLC owned about 0.25% of ResMed worth $27,838,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after buying an additional 13,094,421 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after buying an additional 508,392 shares in the last quarter. State Street Corp grew its stake in shares of ResMed by 2.1% in the first quarter. State Street Corp now owns 4,598,911 shares of the medical equipment provider’s stock valued at $330,983,000 after buying an additional 95,552 shares in the last quarter. FMR LLC grew its stake in shares of ResMed by 1.9% in the first quarter. FMR LLC now owns 4,010,810 shares of the medical equipment provider’s stock valued at $288,659,000 after buying an additional 74,389 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of ResMed by 1.2% in the second quarter. Bank of New York Mellon Corp now owns 2,266,663 shares of the medical equipment provider’s stock valued at $176,505,000 after buying an additional 25,925 shares in the last quarter. 60.25% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/09/12/stephens-investment-management-group-llc-has-27-84-million-position-in-resmed-inc-rmd.html.
In other ResMed news, Director Peter C. Farrell sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $76.74, for a total value of $1,534,800.00. Following the completion of the transaction, the director now owns 314,800 shares in the company, valued at approximately $24,157,752. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $77.44, for a total value of $96,800.00. Following the completion of the transaction, the chief financial officer now owns 60,508 shares of the company’s stock, valued at approximately $4,685,739.52. The disclosure for this sale can be found here. Insiders sold a total of 204,649 shares of company stock valued at $15,635,958 in the last 90 days. Corporate insiders own 1.97% of the company’s stock.
ResMed Inc. (NYSE RMD) traded down 0.45% during trading on Tuesday, reaching $81.01. 74,826 shares of the company’s stock were exchanged. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of 33.75 and a beta of 0.79. The firm’s 50-day moving average price is $75.31 and its 200-day moving average price is $73.08. ResMed Inc. has a 12 month low of $56.59 and a 12 month high of $81.29.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.02. The firm had revenue of $556.69 million during the quarter, compared to the consensus estimate of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 EPS. On average, equities research analysts anticipate that ResMed Inc. will post $3.03 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 1.72%. The ex-dividend date of this dividend is Tuesday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.33. ResMed’s dividend payout ratio is 58.09%.
Several research firms recently weighed in on RMD. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a research note on Friday. Credit Suisse Group cut shares of ResMed from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 8th. Zacks Investment Research cut shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. BMO Capital Markets raised their target price on shares of ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research note on Wednesday, August 2nd. Finally, Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $67.86.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.